bioAffinity Technologies, Inc.
NASDAQTotal Valuation
bioAffinity Technologies, Inc. carries a market capitalization of 3.19M, placing it among publicly traded companies globally. Its enterprise value stands at -1.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.19M |
| Enterprise Value | -1.72M |
Share Statistics
bioAffinity Technologies, Inc. currently has 4.50M shares outstanding.
| Shares Outstanding | 4.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
bioAffinity Technologies, Inc. maintains a current ratio of 1.36, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.76, indicating elevated leverage, while an interest coverage ratio of -255.72 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.36 |
| Quick Ratio | 1.19 |
| Debt / Equity | 37.76 |
| Debt / EBITDA | -0.12 |
| Interest Coverage | -255.72 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -235.39 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 64.93 |
Taxes
| Income Tax | 35,347.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
bioAffinity Technologies, Inc.'s stock has declined approximately -47.36842% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 0.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | -47.36842% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.27 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -11.15M, while operating income came in at -11.62M.
| Revenue | 5.61M |
| Gross Profit | 1.82M |
| Operating Income | -11.62M |
| Pretax Income | -15.84M |
| Net Income | -15.88M |
| EBITDA | -11.15M |
| EBIT | -11.62M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
bioAffinity Technologies, Inc. holds 3.10M in cash and equivalents against 1.38M in total debt, resulting in a net debt position of -3.00M. Total book value stands at -72.15M, with working capital of 1.16M providing operational flexibility.
| Cash & Cash Equivalents | 3.10M |
| Total Debt | 1.38M |
| Net Debt | -3.00M |
| Equity (Book Value) | -72.15M |
| Book Value Per Share | N/A |
| Working Capital | 1.16M |
Cash Flow
bioAffinity Technologies, Inc. produced -10.91M in operating cash flow over the past twelve months.
| Operating Cash Flow | -10.91M |
| Capital Expenditures | -15,445.00 |
| Free Cash Flow | -10.93M |
| FCF Per Share | N/A |
Margins
bioAffinity Technologies, Inc. operates with a gross margin of 32.44, reflecting its pricing power and cost economics. The operating margin of -207.22 and net profit margin of -283.27 provide insight into operational efficiency.
| Gross Margin | 32.44 |
| Operating Margin | -207.22 |
| Pretax Margin | -282.64 |
| Profit Margin | -283.27 |
| EBITDA Margin | -198.93 |
Scores
bioAffinity Technologies, Inc. posts an Altman Z-Score of -22.68, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -22.68 |